Viewing StudyNCT00509379



Ignite Creation Date: 2024-05-05 @ 6:34 PM
Last Modification Date: 2024-10-26 @ 9:35 AM
Study NCT ID: NCT00509379
Status: COMPLETED
Last Update Posted: 2011-01-28
First Post: 2007-07-30

Brief Title: Non-randomized Safety Study With BortezomibRituximab in RelapsedRefractory Indolent Lymphoma
Sponsor: Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie
Organization: Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie

Conditions & Keywords Data

Conditions:
Name
Non-Hodgkin Lymphoma
Lymphoma
Keywords:
Name View
Relapsedrefractory indolent lymphoma View
Non-follicular Lymphoma View
Mantle cell non-Hodgkin Lymphoma View
Patients naïve or sensitive to rituximab View
Patients not eligible for high dose chemotherapy with ASCT View